Dopamine and Libido
Apomorphine, dopamine agonists, and Parkinson's-medication hypersexuality
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Sublingual apomorphine (Uprima/Ixense) approved in EU ~2001, never approved in US; withdrawn from EU market
Reference only. Not medical advice.
What can go wrong
Apomorphine causes nausea, dizziness, and syncope; it is not a benign 'natural' molecule despite the name (it contains no morphine and is not an opioid). Dopamine agonists used for Parkinson's carry a documented risk of impulse control disorders including hypersexuality, pathological gambling, and compulsive shopping, which can be socially and financially devastating and may resolve only on dose reduction. No consumer supplement safely or selectively raises dopamine to enhance libido; products marketed on 'dopamine for drive' (e.g., L-DOPA-containing Mucuna preparations) are not validated for sexual function and carry real risks.
This is something to take to a clinician. The Atlas can tell you what is known about dopamine and libido in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Dopamine is the principal pro-sexual neurotransmitter of the brain, driving the appetitive 'wanting' phase of desire through mesolimbic and hypothalamic pathways. Apomorphine, a non-selective dopamine agonist, was developed as the first centrally-acting ED drug (sublingual Uprima/Ixense) and approved in Europe around 2001, but its modest efficacy and prominent nausea, and the arrival of PDE5 inhibitors, doomed it commercially; it was withdrawn. The clearest human evidence that dopamine drives libido comes from an unintended source: dopamine-agonist therapy for Parkinson's disease causes pathological hypersexuality in a substantial minority of patients.
The neurotransmitter of wanting, and the cautionary tale of trying to drug it.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Mesolimbic dopamine (ventral tegmental area to nucleus accumbens) encodes incentive salience, the motivational 'pull' toward a sexual cue, while hypothalamic dopamine in the MPOA and PVN facilitates the autonomic machinery of erection. Apomorphine stimulates D1/D2 receptors, including in the PVN, to promote erection centrally; the same agonism at the area postrema (a circumventricular nausea center) drives its dose-limiting emesis.
The Parkinson's natural experiment
Impulse control disorders, including compulsive hypersexuality, are a recognized class effect of dopamine agonists (pramipexole, ropinirole) used in Parkinson's disease and restless legs. The DOMINION cross-sectional study (Weintraub et al., 2010) found impulse control disorders in roughly 13.6% of treated patients, with dopamine-agonist use associated with a 2-3x increased odds. This is the strongest causal human evidence that dopaminergic tone scales sexual drive, and a warning that crudely boosting dopamine produces compulsion, not healthy desire.
Safety in detail
Dopaminergic agents and apomorphine require physician supervision; dopamine agonists carry a documented risk of impulse control disorders. Self-medicating for libido with dopaminergic supplements is not supported by evidence and may cause harm.
What people get wrong
Often saidApomorphine is a natural opioid aphrodisiac
ActuallyIt is a synthetic dopamine agonist with no opioid activity; the name reflects its chemical derivation from morphine, not its pharmacology. It was a real but commercially failed ED drug.
Often saidBoosting dopamine with supplements safely increases sex drive
ActuallyThe Parkinson's literature shows dopaminergic stimulation can cause compulsive hypersexuality, not balanced desire, and no OTC product is validated for this. Crude dopamine elevation is a liability, not a libido hack.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Apomorphine's pro-erectile effect was noted decades before its clinical trials; TAP/Abbott and others developed sublingual formulations in the 1990s, winning European approval as Uprima/Ixense around 2001. Sildenafil's 1998 launch had already captured the market, and apomorphine's nausea and modest efficacy sealed its decline. Meanwhile, neurologists increasingly recognized through the 2000s that dopamine agonists for Parkinson's could unleash hypersexuality, cementing dopamine's role in human sexual motivation.
- 1990sSublingual apomorphine developed as centrally-acting ED candidate
- 1998Sildenafil launches, dominating ED market
- ~2001Apomorphine (Uprima/Ixense) approved in EU
- 2003-2010Dopamine-agonist impulse control disorders recognized in Parkinson's
- 2010sApomorphine withdrawn from EU ED market
At a glance
- Apomorphine EU approval
- ~2001 (sublingual)
- US status
- Never FDA-approved for ED
- Limiting side effect
- Nausea/vomiting (area postrema D2)
- Parkinson's ICD prevalence
- ~14-17% of dopamine-agonist-treated patients (DOMINION study)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Dopamine and Libido. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Heaton, apomorphine sublingual for ED2000
Demonstrated centrally-mediated erections with sublingual apomorphine in men with ED, establishing proof of concept for a CNS-acting agent
Weintraub et al., DOMINION study2010
Found impulse control disorders in ~13.6% of Parkinson's patients; dopamine-agonist therapy strongly associated with hypersexuality and other compulsions
Hull et al., dopamine and male sexual behavior1999
Established that MPOA dopamine release facilitates copulation and genital reflexes in male rats